Award

Targeting DNA repair in KRAS mutated lung cancer by chemical screening

Description: The overall goal of this proposal is to illustrate molecular mechanisms and biological actions of cardiac glycosides on inhibiting KRAS mutant lung cancers. Knowledge gained through the support of this project may lead to new discovery of unique approaches to treat KRAS mutant lung cancers, which lack effective treatment to date. These studies will improve the lifespan of patients with KRAS mutant lung cancers in the US.

Funder: National Cancer Institute

Funding type: research

Funder scheme: R01

Start date: 2019-07-01

End date: 2025-06-30

Investigator: YOU-WEI ZHANG

Institution: CASE WESTERN RESERVE UNIVERSITY

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

Funded outputs count: 18

Funder award ID: R01CA230453

OpenAlex ID: G5228721313

Plasticity of the mammalian integrated stress response

2025 · Chien-Wen Chen, David Papadopoli, et al. · Nature · 50

The Plasmodium falciparum NCR1 transporter is an antimalarial target that exports cholesterol from the parasite’s plasma membrane

2024 · Zhemin Zhang, Meinan Lyu, et al. · Science Advances · 7

Physiology and pharmacological targeting of phase separation

2024 · Fangfang Wang, Youwei Zhang · Journal of Biomedical Science · 28

The mechanistic role of cardiac glycosides in DNA damage response and repair signaling

2023 · Diana Ainembabazi, Youwei Zhang, et al. · Cellular and Molecular Life Sciences · 18

MYO10 regulates genome stability and cancer inflammation through mediating mitosis

2023 · Franklin Mayca Pozo, Xinran Geng, et al. · Cell Reports · 14

A novel sorbicillinoid compound as a potent anti‐inflammation agent through inducing NLRP3 protein degradation

2023 · Fangfang Wang, Meng Zhang, et al. · British Journal of Pharmacology · 13

Synthesis and Biological Evaluation of Cardiac Glycosides for Cancer Therapy by Targeting the DNA Damage Response

2022 · Diana Ainembabazi, Xinran Geng, et al. · ChemMedChem · 10

Phase ‘separating’ 53BP1 from DSB repair

2022 · Youwei Zhang · Genes & Diseases · 3

53BP1 regulates heterochromatin through liquid phase separation

2022 · Lei Zhang, Xinran Geng, et al. · Nature Communications · 104

The ‘New (Nu)-clear’ evidence of the tumor-driving role of PI3K

2022 · Franklin Mayca Pozo, Tony Hunter, et al. · Acta Materia Medica · 23

Adaptive translational pausing is a hallmark of the cellular response to severe environmental stress

2021 · Raul Jobava, Yuanhui Mao, et al. · Molecular Cell · 48

MYO10 drives genomic instability and inflammation in cancer

2021 · Franklin Mayca Pozo, Xinran Geng, et al. · Science Advances · 37

Cardiac glycosides inhibit cancer through Na/K-ATPase-dependent cell death induction

2020 · Xinran Geng, Fangfang Wang, et al. · Biochemical Pharmacology · 35

Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy

2020 · Danmei Tian, Jinshan Tang, et al. · Cancer Letters · 31

Protein phosphatase 2A controls ongoing DNA replication by binding to and regulating cell division cycle 45 (CDC45)

2019 · Abbey L. Perl, Caitlin M. O’Connor, et al. · Journal of Biological Chemistry · 16

Harmines inhibit cancer cell growth through coordinated activation of apoptosis and inhibition of autophagy

2018 · Xinran Geng, Yichang Ren, et al. · Biochemical and Biophysical Research Communications · 33

Caffeine Protects Skin from Oxidative Stress-Induced Senescence through the Activation of Autophagy

2018 · Yi-Fang Li, Shu-Hua Ouyang, et al. · Theranostics · 198

Le projet Réseau 2000 de la RATP

1988 · Georges Amar · Dialnet (Universidad de la Rioja)